Ragaglitazar (BioDeep_00000837824)

   


代谢物信息卡片


(-)-3-(4-(2-(Phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoic acid

化学式: C25H25NO5 (419.173264)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCOC(CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
InChI: InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)

描述信息

C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist

同义名列表

3 个代谢物同义名

(-)-3-(4-(2-(Phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoic acid; Ragaglitazar(racemate); Ragaglitazar



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yoshihiro Shibata, Katsuji Kagechika, Mitsuhiro Yamaguchi, Hideo Kubo, Hiroyuki Usui. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1). Bioorganic & medicinal chemistry letters. 2012 Dec; 22(23):7075-9. doi: 10.1016/j.bmcl.2012.09.092. [PMID: 23084275]
  • B Chopra, N T Georgopoulos, A Nicholl, J Hinley, M B Oleksiewicz, J Southgate. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Cell proliferation. 2009 Oct; 42(5):688-700. doi: 10.1111/j.1365-2184.2009.00628.x. [PMID: 19614673]
  • C L Brand, E D Galsgaard, D Tornehave, J Rømer, C F Gotfredsen, K Wassermann, L B Knudsen, A Vølund, J Sturis. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes, obesity & metabolism. 2009 Aug; 11(8):795-803. doi: 10.1111/j.1463-1326.2009.01049.x. [PMID: 19519868]
  • Venkata V Pavankuamr, C A Vinu, Ramesh Mullangi, Nuggehally R Srinivas. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. European journal of drug metabolism and pharmacokinetics. 2007 Jan; 32(1):29-37. doi: 10.1007/bf03190987. [PMID: 17479541]
  • Sudhir Sharma, Angaru Sowjanya, Manju Kumari, Raichur Suryaprakash, Gershome Cynthia, Juluri Suresh, Ranjan Chakrabarti. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar. Life sciences. 2006 Dec; 80(3):235-44. doi: 10.1016/j.lfs.2006.09.009. [PMID: 17014868]
  • Prem K Mamnoor, Pragathi Hegde, Srinivas R Datla, Ravi K B Damarla, Ramanujam Rajagopalan, Ranjan Chakrabarti. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator. Pharmacological research. 2006 Aug; 54(2):129-35. doi: 10.1016/j.phrs.2006.03.020. [PMID: 16651004]
  • Alexander Tenenbaum, Michael Motro, Enrique Z Fisman. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular diabetology. 2005 Sep; 4(?):14. doi: 10.1186/1475-2840-4-14. [PMID: 16168052]
  • Lucy C Pickavance, Christian L Brand, Karsten Wassermann, John P H Wilding. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. British journal of pharmacology. 2005 Feb; 144(3):308-16. doi: 10.1038/sj.bjp.0706041. [PMID: 15655531]
  • Martin B Oleksiewicz, Inger Thorup, Henriette S Nielsen, Hanne V Andersen, Anne Charlotte Hegelund, Lars Iversen, Torben S Guldberg, Peter R Brinck, Ingrid Sjogren, Ulla K Thinggaard, Lis Jørgensen, Marianne B Jensen. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicologic pathology. 2005; 33(5):552-60. doi: 10.1080/01926230500214657. [PMID: 16076770]
  • Kota Jagannath, Madhusudana Rao Chaluvadi, Ramesh Mullangi, N V S Rao Mamidi, Nuggehally R Srinivas. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. Biopharmaceutics & drug disposition. 2004 Oct; 25(7):323-8. doi: 10.1002/bdd.413. [PMID: 15386480]
  • S Syed Mustafa, Ravikumar Trivedi, N V S R Mamidi, Ramesh Mullangi, Nuggehally R Srinivas. Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Sep; 809(1):23-30. doi: 10.1016/j.jchromb.2004.05.030. [PMID: 15282089]
  • Mohammed F Saad, Susan Greco, Kwame Osei, Andrew J Lewin, Christopher Edwards, Margarita Nunez, Rickey R Reinhardt. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes care. 2004 Jun; 27(6):1324-9. doi: 10.2337/diacare.27.6.1324. [PMID: 15161783]
  • Harald Stingl, Michael Roden. [Future targets in the treatment of type 2 diabetes]. Wiener klinische Wochenschrift. 2004 Apr; 116(7-8):217-29. doi: 10.1007/bf03041051. [PMID: 15143860]
  • B K Skrumsager, K K Nielsen, M Müller, G Pabst, P G Drake, B Edsberg. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. Journal of clinical pharmacology. 2003 Nov; 43(11):1244-56. doi: 10.1177/0091270003257230. [PMID: 14551179]
  • Ranjan Chakrabarti, Reeba K Vikramadithyan, Parimal Misra, Jagadheshan Hiriyan, Suryaprakash Raichur, Ravi K Damarla, Cynthia Gershome, Juluri Suresh, Ramanujam Rajagopalan. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. British journal of pharmacology. 2003 Oct; 140(3):527-37. doi: 10.1038/sj.bjp.0705463. [PMID: 12970088]
  • Philip J Larsen, Per Bo Jensen, Rikke V Sørensen, Leif Kongskov Larsen, Niels Vrang, Erik M Wulff, Karsten Wassermann. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes. 2003 Sep; 52(9):2249-59. doi: 10.2337/diabetes.52.9.2249. [PMID: 12941763]
  • Gurram R Madhavan, Vadla Balraju, Bejugam Mallesham, Ranjan Chakrabarti, Vidya B Lohray. Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents. Bioorganic & medicinal chemistry letters. 2003 Aug; 13(15):2547-51. doi: 10.1016/s0960-894x(03)00490-6. [PMID: 12852963]
  • Michael P Andersen, Karin K Nielsen. Determination of ragaglitazar, a novel dual acting peroxisome proliferator-activated receptor (PPAR) alpha and -gamma agonist, in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 May; 788(1):45-55. doi: 10.1016/s1570-0232(02)01014-0. [PMID: 12668070]
  • Christian L Brand, Jeppe Sturis, Carsten F Gotfredsen, Jan Fleckner, Christian Fledelius, Bo F Hansen, Birgitte Andersen, Ji-Ming Ye, Per Sauerberg, Karsten Wassermann. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. American journal of physiology. Endocrinology and metabolism. 2003 Apr; 284(4):E841-54. doi: 10.1152/ajpendo.00348.2002. [PMID: 12475752]
  • Ji-Ming Ye, Miguel A Iglesias, David G Watson, Bronwyn Ellis, Leonie Wood, Per Bo Jensen, Rikke Veggerby Sørensen, Philip Just Larsen, Gregory J Cooney, Karsten Wassermann, Edward W Kraegen. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. American journal of physiology. Endocrinology and metabolism. 2003 Mar; 284(3):E531-40. doi: 10.1152/ajpendo.00299.2002. [PMID: 12556350]
  • Jagannath Kota, Ramesh Mullangi, Rao N V S Mamidi, Ramanujam Rajagopalan. Quantitative determination of ragaglitazar in rat plasma by HPLC: validation and application in pharmacokinetic study. Biomedical chromatography : BMC. 2002 Dec; 16(8):495-9. doi: 10.1002/bmc.190. [PMID: 12474210]
  • Per Sauerberg, Ingrid Pettersson, Lone Jeppesen, Paul S Bury, John P Mogensen, Karsten Wassermann, Christian L Brand, Jeppe Sturis, Helle F Wöldike, Jan Fleckner, Anne-Sofie T Andersen, Steen B Mortensen, L Anders Svensson, Hanne B Rasmussen, Søren V Lehmann, Zdenek Polivka, Karel Sindelar, Vladimira Panajotova, Lars Ynddal, Erik M Wulff. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. Journal of medicinal chemistry. 2002 Feb; 45(4):789-804. doi: 10.1021/jm010964g. [PMID: 11831892]
  • B B Lohray, V B Lohray, A C Bajji, S Kalchar, R R Poondra, S Padakanti, R Chakrabarti, R K Vikramadithyan, P Misra, S Juluri, N V Mamidi, R Rajagopalan. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. Journal of medicinal chemistry. 2001 Aug; 44(16):2675-8. doi: 10.1021/jm010143b. [PMID: 11472221]